Edwards Lifesciences (EW) Stock Statistics & Valuation Metrics

Edwards Lifesciences has a market cap or net worth of CHF35.23B. The enterprise value is CHF44.81B.

Edwards Lifesciences has 580,300,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Edwards Lifesciences’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 11.40%.

The current PE Ratio of Edwards Lifesciences is 46.4. Edwards Lifesciences’s PEG ratio is -0.63.

In the last 12 months, Edwards Lifesciences had revenue of 6.07B and earned 1.07B in profits. Earnings per share was 1.84.

In the last 12 months, operating cash flow was 1.60B and capital expenditures -260.20M, giving a free cash flow of 1.33B billion.

Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―

Edwards Lifesciences upcoming earnings date is Apr 23, 2026, After Close (Confirmed).

Edwards Lifesciences as a current ratio of 3.72, with Debt / Equity ratio of 6.82%

In the past 12 months, Edwards Lifesciences has paid 216.90M in taxes.

Edwards Lifesciences EV to EBITDA ratio is 33.31, with an EV/FCF ratio of 35.67.

Edwards Lifesciences has CHF4.23B in cash and marketable securities with CHF705.40M in debt, giving a net cash position of CHF3.52B billion.

Gross margin is 78.11%, with operating margin of 26.97%, and net profit margin of 17.69%.

The average price target for Edwards Lifesciences is CHF75.59, which is 11.43% higher than the current price. The consensus rating is Moderate Buy